| http://www.w3.org/ns/prov#value | - But a year later, sales fell sharply as competition came online, especially Gilead Sciences' (GILD) Sovaldi, which has already surpassed Incivek's launch record since it was approved in December.In 2012 ivacaftor, one of the two drugs in the latest study, was approved for sale as Kalydeco.
|
